managing coexistent inflammatory bowel disease in patients with psc themos dassopoulos, m.d....
TRANSCRIPT
![Page 1: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/1.jpg)
Managing Coexistent Inflammatory Bowel Disease in Patients with PSC
Themos Dassopoulos, M.D.Director, Baylor Center for IBD
www.centerforibd.com
April 24, 2015
![Page 2: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/2.jpg)
No disclosures
![Page 3: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/3.jpg)
The Basics!• What is IBD? • You’re not alone - How common is IBD?• It’s not your fault - What causes IBD?• What are the symptoms and complications of IBD?• Until there is a cure - How is IBD treated?• Is IBD different in patients with PSC?• Am I what I eat? - What is the role of diet?• What is the role of stress?• Tips for managing IBD and staying well
![Page 4: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/4.jpg)
Inflammatory Bowel Diseases (IBD)
• Disorders of chronic bowel inflammation• Inappropriate immune reaction to normal bacteria in
genetically susceptible individuals
![Page 5: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/5.jpg)
Types of IBD
CROHN’S DISEASE (CD) • Patchy, full-thickness inflammation• Mouth to anus involvement,
mostly lower small intestine and colon• Fistulas, abscesses, strictures• Worsens with smoking
IndeterminateColitis
10%-15%
ULCERATIVE COLITIS (UC)• Continuous, inflammation of the
lining (mucosa) of the colon• Colon only
![Page 6: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/6.jpg)
Inflammatory Bowel Diseases (IBD)
• Disorders of chronic bowel inflammation• Inappropriate immune reaction to normal bacteria in
genetically susceptible individuals
• The IBDs are not– Food allergies– Food sensitivities– Infections– Irritable bowel syndrome (IBS)
![Page 7: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/7.jpg)
![Page 8: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/8.jpg)
How common is IBD?
• 1 to 1.5 million Americans suffer from IBD• 80,000 hospitalizations per year• 18,000 surgeries per year
• CD medical costs $18,963 / year• UC medical costs $15,020 / year
• Increasing in the pediatric population• Increasing in the developing world
![Page 9: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/9.jpg)
What causes IBD?
Inflammation
Abnormal gut flora• Diet• Antibiotics• Infections
Modifiers:• Smoking• NSAIDs
• Defective clearance of bacteria• Mucosal inflammatory responses• Barrier function of mucosa
EnvironmentGenetics
Over 150 genes!
![Page 10: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/10.jpg)
Over 160 genes500-1000 microbial species
Multiple environmental factors
![Page 11: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/11.jpg)
Over 160 genes500-1000 microbial species
Multiple environmental factors
Each IBD patient is unique The course of the disease differs
from person to person
![Page 12: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/12.jpg)
• Bloody diarrhea• False alarms• Abdominal pain
Ulcerative Colitis
![Page 13: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/13.jpg)
Endoscopic scoreUlcerative Colitis
![Page 14: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/14.jpg)
Crohn’s disease
![Page 15: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/15.jpg)
Inflammatory PenetratingFistulae and Abscesses
Stricturing
PainDiarrhea
PainDistensionVomitingFear of eatingWeight lossRumbling bowel sounds
Presentations of Crohn’s
PainFeverNight sweatsWeight loss
![Page 16: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/16.jpg)
Inflammatory PenetratingFistulae and Abscesses
Stricturing
PainDiarrhea
PainDistensionVomitingFear of eatingWeight lossRumbling bowel sounds
Presentations of Crohn’s
PainFeverNight sweatsWeight loss
![Page 17: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/17.jpg)
Inflammatory PenetratingFistulae and Abscesses
Stricturing
PainDiarrhea
PainDistensionVomitingFear of eatingWeight lossRumbling bowel sounds
Presentations of Crohn’s
PainFeverNight sweatsWeight loss
![Page 18: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/18.jpg)
Inflammatory PenetratingFistulae and Abscesses
Stricturing
PainDiarrhea
PainDistensionVomitingFear of eatingWeight lossRumbling bowel sounds
Presentations of Crohn’s
PainFeverNight sweatsWeight loss
![Page 19: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/19.jpg)
Joint Peripheral arthritisSacroiliitisAnkylosing spondylitis
Skin Erythema NodosumPyoderma Gangrenosum
Liver Primary Sclerosing Cholangitis
Eye EpiscleritisIritis
Extra-intestinal Manifestations
![Page 20: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/20.jpg)
Other complications• Anemia (multiple causes)• Steroid-dependence• Osteoporosis• Malabsorption (CD of the small bowel)– Vitamin B12– Vitamin D
• Colorectal cancer (UC and CD of the colon)• Thrombosis and pulmonary embolism• Toxic megacolon
![Page 21: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/21.jpg)
Risk of colon cancer in colitis
• Risk was greater than 20% in older studies
• The risk has declined significantly in more recent studies
• The risk remains high in patients with:– Longstanding pancolitis with significant mucosal injury– PSC: Approximately 30%
Patients with PSC and colitis should have an
ANNUAL colonoscopy
![Page 22: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/22.jpg)
Clinical features of colon cancer inpatients with colitis and PSC
• Younger at diagnosis of colon cancer
• More advanced, right-sided colon cancer
• Possibly higher cancer risk if dominant stenosis
• The increased risk of colon cancer persists after liver transplantation
Patients with PSC and colitis should have an ANNUAL
colonoscopy even after liver transplantation
![Page 23: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/23.jpg)
Other complications• Anemia (multiple causes)• Steroid-dependence• Osteoporosis• Malabsorption (CD of the small bowel)– Vitamin B12– Vitamin D
• Colorectal cancer (UC and CD of the colon)• Thrombosis and pulmonary embolism• Toxic megacolon
![Page 24: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/24.jpg)
Quality of life
• Bowel function• Depression• Work and school attendance• Reproductive decisions
![Page 25: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/25.jpg)
Informed, Empowered
Patient
PreparedProviders
CommunityHealth System
SelfManagement
Support
ClinicalInformation
Systems
DecisionSupport
DeliverySystem
Wellness, improved function and quality of lifeMonitoring and prevention of complications
Chronic Care Model
Wagner EH Effective Clinical Practice 1998
![Page 26: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/26.jpg)
Goals of Therapy• Induction of remission• Maintenance of remission• Improved quality of life
![Page 27: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/27.jpg)
Goals of Therapy• Induction of remission• Maintenance of remission• Improved quality of life• Prevention of complications• Restoring and maintaining nutrition• Optimization of surgical intervention
![Page 28: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/28.jpg)
Goals of Therapy• Induction of remission• Maintenance of remission• Improved quality of life• Prevention of complications• Restoring and maintaining nutrition• Optimization of surgical intervention• Mucosal healing
![Page 29: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/29.jpg)
Mucosal Healing
Before therapy After therapy
Mucosal Healing results infewer hospitalizations and surgeries
![Page 30: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/30.jpg)
Classes of IBD therapiesAminosalicylates(UC, CD)
• Sulfasalazine (Asulfidine)• Mesalamine (5ASA)
(Asacol, Pentasa, Colazal, Lialda, Apriso)• 5ASA enemas and suppositories
(Rowasa enemas, Canasa suppositories)
![Page 31: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/31.jpg)
Classes of IBD therapiesAminosalicylates(UC, CD)
• Sulfasalazine (Asulfidine)• Mesalamine (5ASA)
(Asacol, Pentasa, Colazal, Lialda, Apriso)• 5ASA enemas and suppositories
(Rowasa enemas, Canasa suppositories)
Antibiotics (CD)* • Ciprofloxacin (CD) (Cipro)• Metronidazole (CD) (Flagyl)
*Antibiotics are used for CD of the colon and to prevent post-operative recurrence of CD. They are not used in UC.
![Page 32: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/32.jpg)
Classes of IBD therapiesAminosalicylates(UC, CD)
• Sulfasalazine (Asulfidine)• Mesalamine (5ASA)
(Asacol, Pentasa, Colazal, Lialda, Apriso)• 5ASA enemas and suppositories
(Rowasa enemas, Canasa suppositories)
Antibiotics (CD) • Ciprofloxacin (CD) (Cipro)• Metronidazole (CD) (Flagyl)
Corticosteroids(UC, CD)
• Prednisone• Budesonide (ileocolic, colonic release)
(Entocort, Uceris)• Rectal (hydrocortisone enemas, foam)
(Cortenema, Cortifoam)• IV (methyprednisolone,hydrocortisone)
![Page 33: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/33.jpg)
Classes of IBD therapies
Immunomodulators
• 6-mercaptopurine (CD, UC)(Purinethol)• Azathioprine (CD,UC) (Imuran)• Methotrexate (CD)
![Page 34: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/34.jpg)
Classes of IBD therapies
Immunomodulators
• 6-mercaptopurine (CD, UC)(Purinethol)• Azathioprine (CD,UC) (Imuran)• Methotrexate (CD)
Anti-TNF • Infliximab (CD,UC) (Remicade)• Adalimumab (CD,UC) (Humira)• Certolizumab (CD) (Cimzia)• Golimumab (UC) (Simponi)
![Page 35: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/35.jpg)
Classes of IBD therapies
Immunomodulators
• 6-mercaptopurine (CD, UC)(Purinethol)• Azathioprine (CD,UC) (Imuran)• Methotrexate (CD)
Anti-TNF • Infliximab (CD,UC) (Remicade)• Adalimumab (CD,UC) (Humira)• Certolizumab (CD) (Cimzia)• Golimumab (UC) (Simponi)
Anti-4 integrin • Natalizumab (CD) (Tysabri)• Vedolizumab (UC, CD) (Entyvio)
![Page 36: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/36.jpg)
Lessons we have learned Treating the disease early gives the best results
Adherence to treatment is key
Rectal therapies are critical for UC
Steroids do not heal the inflammation of CD
The most effective medications are– Immunomodulators – Anti-TNF agents– Immunomodulators + anti-TNF (most effective)
Benefits far outweigh the risks
![Page 37: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/37.jpg)
The role of surgery in UC
• Surgery is not necessarily a bad outcome
• Colectomy cures ulcerative colitis
![Page 38: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/38.jpg)
Proctocolectomy with end-ileostomy
![Page 39: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/39.jpg)
Proctocolectomy withileal pouch-anal anastomosis
Kirat and Remzi, Clin Colon Rectal Surg 2010
Ileum
Colon
Ileal Pouch
![Page 40: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/40.jpg)
The role of surgery in CD
• Bowel resection for CD removes the diseased bowel and allows a fresh start
• BUT, prevent post-operative recurrence
![Page 41: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/41.jpg)
Strictureplasty
![Page 42: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/42.jpg)
Primary Sclerosing Cholangitis in IBD
• Over 60% of patients with PSC also have IBD:‒ UC 80%‒ CD 10%‒ Indeterminate colitis 10%
• 3–8% of patients with UC have PSC
• 1–3% of patients with CD have PSC
• The activities of IBD and PSC are independent
Every patient with PSC should be screened for colitis
Treating the IBD does not affect the PSC
![Page 43: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/43.jpg)
Colitis with coexistent PSC is “different”
• Pancolitis with rectal sparing• Mild ileitis• Mild activity – occasionally asymptomaticLess likely to require colectomy because of
resistant colitis• Increased mortality from colon cancer, liver
failure, and cholangiocarcinoma
![Page 44: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/44.jpg)
What happens after liver transplantation?IBD• Variable course of colitis• Risk of colon cancer remains high
Liver Disease• Increased risk of PSC recurrence in patients with
intact colons• The presence or severity of IBD does not influence
the occurrence of recurrent PSC or patient survival
![Page 45: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/45.jpg)
What happens after colectomy?
After ileal-pouch anal anastomosis• Increased risk of pouchitis• No increased risk of pouch failure • Similar quality of life• Higher long-term mortality
After end ileostomy• Parastomal varices (40-50%)
![Page 46: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/46.jpg)
Diet and IBD
• The Western diet is one of the causes of IBD
• No particular food or diet cures IBD
• Some patients report improved symptoms with specific diets
• BUT, diets can be restrictive and difficult to follow
![Page 47: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/47.jpg)
Which diet might help prevent IBD?
• Lower intake of n-6 polyunsaturated fatty acids– Arachidonic acid and Linoleic acid
(red meat, margarines, oils derived from soya, sunflower, rapeseed, poppyseed, and corn)
• Higher intake of n-3 polyunsaturated fatty acids– Perilla oil, fish oil, sardines, salmon
• Higher intake of dietary fiber• Lower intake of sugars
![Page 48: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/48.jpg)
Diet: Specific situations• Coexistent conditions – avoid the food culprit– Lactose or fructose intolerance– Celiac disease– Non-celiac gluten sensitivity– Irritable bowel syndrome – FODMAP diet– Food allergies
• Flares– Bland diet (avoid fat, caffeine, alcohol and fiber)
• Obstruction– Low residue diet (avoid insoluble fiber: seeds, nuts,
beans, green leafy vegetables, wheat bran)
![Page 49: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/49.jpg)
Stress and IBD
• Many patients report flares precipitated by stress– It’s not only what the patient eats… but also what eats the patient
• Anxiety, depression, support structures, coping strategies, and perception of illness affect course of illness
• Patients should be screened for psychological distress
• Psychological interventions improve quality of life, anxiety and depression
![Page 50: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/50.jpg)
Tips for managing IBD and staying well
• Educate yourself• Learn your disease• Come prepared• Ask questions• Be your own advocate• Manage stress and diet• Have a plan
![Page 51: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/51.jpg)
Tips for managing IBD and staying well
• Educate yourself• Learn your disease• Come prepared• Ask questions• Be your own advocate• Manage stress and diet• Have a plan
• Avoid aspirin and NSAIDs• Stop smoking• Take your medications• Maintain bone health• Be vigilant about infection• Keep vaccinations up-to-date• Get scoped annually
(if you have colitis and PSC)
![Page 52: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/52.jpg)
Putting it all together
• The IBDs are complex diseases– Each patient is unique
• Chronic disease management– Patient education and empowerment– Collaboration between primary provider,
gastroenterologist, hepatologist and other providers• The future of IBD care and research is bright!
![Page 53: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/53.jpg)
Additional slides
![Page 54: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/54.jpg)
Aminosalicylates
• Sulfasalazine • Mesalamine (5ASA)• 5ASA enemas and suppositories
• Use: UC, Mild Crohn’s colitis• AE: Paradoxical diarrhea, nephrotoxicity
![Page 55: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/55.jpg)
Antibiotics
• Ciprofloxacin• Use: Mild Crohn’s colitis
Perianal disease• AE: Tendinitis, tendon rupture, C. difficile
•Metronidazole• Use: Mild Crohn’s colitis
Prevention of postoperative recurrencePerianal disease
• AE: Peripheral neuropathy
![Page 56: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/56.jpg)
Corticosteroids
• Prednisone• Budesonide• Ileocolic release • Colonic release
• Topical • Hydrocortisone enemas, foams and suppositories• Budesonide foam
• IV (methyprednisolone,hydrocortisone)
• Use: Induction of remission in UC and CDNOT maintenance
![Page 57: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/57.jpg)
Thiopurines• Azathioprine Mercaptopurine
• Maintenance of steroid induced remission (CD,UC)• Perianal disease (CD)• Prevention of post-operative recurrence (CD)• Reduction of anti-TNF immunogenicity
Leukopenia (10-20%) Non-melanoma skin cancer
Transaminitis (10-20%) Bacterial infections (with neutropenia)
Pancreatitis (3%) Reactivation of HBV
Herpes zoster Lymphoma (4-6/10,000/year)
CMV colitis Nodular regenerative hyperplasia
![Page 58: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/58.jpg)
Methotrexate
• Maintenance of steroid induced remission (CD)• Reduction of anti-TNF immunogenicity (CD,UC)
Nausea, emesis, fatigue (give folic acid)StomatitisLeukopeniaLiver fibrosis and cirrhosisInterstitial pneumonitis and pulmonary fibrosisInfections are rare
No reports of lymphoma
![Page 59: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/59.jpg)
Anti-TNF• Infliximab (Remicade), adalimumab (Humira),
certolizumab pegol (Cimzia), golimumab (Simponi)• Induction and maintenance of remission (CD,UC)• Perianal disease (CD)Infusion reactions Cutaneous reactionsHepatotoxicity CytopeniaInfections: Reactivation of TB, Herpes zoster, HBVEndemic: Histoplasmosis, coccidioidomycosis, blastomycosisOpportunistic: Aspergillosis, cryptococcosis, pneumocystisMelanomaNo proof of increased incidence of lymphoma
![Page 60: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/60.jpg)
Anti-TNF a agents• Similar efficacy – Induction: ≈ 60% response– Maintenance: ≈ 40% response
• Similar safety• Anti-drug antibodies (ADA) (10-15%/year)® Loss of response
• Concomitant immunomodulators – Decrease ADA 14.6% on infliximab vs. 0.9% on combo– Enhance efficacy 44.4% on infliximab vs. 58.8% on combo
![Page 61: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/61.jpg)
• Similar efficacy in luminal disease– Infliximab is faster-acting
• Infliximab is more effective for perianal disease• Similar safety and immunogenicity
Choice of agent also depends on:Cost ConvenienceCompliance
Considerations in selecting anti-TNFa
![Page 62: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/62.jpg)
Anti-Integrin therapies
MAdCAM-1
α4β7
T cell
α4β7
![Page 63: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/63.jpg)
MAdCAM-1T cell
NATAnti-α4
Anti-Integrin therapiesNatalizumab (Tysabri®)
Anti-4 Blocks 47 and 41
Prohibitive risk of PML if JCV Ab (+)
![Page 64: Managing Coexistent Inflammatory Bowel Disease in Patients with PSC Themos Dassopoulos, M.D. Director, Baylor Center for IBD April](https://reader036.vdocuments.us/reader036/viewer/2022062422/56649e6a5503460f94b674ce/html5/thumbnails/64.jpg)
VEDAnti-α4β7
MAdCAM-1T cell
NATAnti-α4
Anti-Integrin therapiesNatalizumab (Tysabri®)
Anti-4 Blocks 47 and 41
Prohibitive risk of PML if JCV Ab (+)
Vedolizumab (Entyvio®)Anti-47
Gut specificNo risk of PML